---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-008080"
form_type: "8-K"
ticker: "COLL"
cik: "0001267565"
company_name: "COLLEGIUM PHARMACEUTICAL, INC"
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T20:48:40.526181+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Collegium reports record Q1 revenue $144.8M, adjusted EPS $1.32, reaffirms FY23 guide

## Summary
- Record product revenue net of $144.8M, up 73% YoY from $83.8M.
- Non-GAAP adjusted net income $51.7M with adjusted EPS $1.32 vs $0.71 YoY.
- Adjusted EBITDA $87.6M, up 101% YoY from $43.5M.
- Cash balance $269.5M; completed $241.5M convertible note offering due 2029.
- Reaffirmed FY23 product revenue $565-580M and adjusted EBITDA $355-370M.

## SEC filing metadata
- accession: 0001558370-23-008080
- form_type: 8-K
- ticker: COLL
- cik: 0001267565
- company_name: COLLEGIUM PHARMACEUTICAL, INC
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1267565/000155837023008080/0001558370-23-008080-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1267565/000155837023008080/coll-20230504x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-008080
- JSON: https://secwatch.observer/filing/0001558370-23-008080.json
- Plain text: https://secwatch.observer/filing/0001558370-23-008080.txt

## Key facts
- Earnings Releases
  COLLEGIUM PHARMACEUTICAL, INC reported Full Year 2023 results: revenue $565.0 to $580.0 million. Guidance reaffirmed.
  - Period: Full Year 2023
  - Revenue: $565.0 to $580.0 million
  - Guidance: reaffirmed
  - Result: guidance update
  source text: The Company reaffirms its full-year 2023 guidance for Product Revenues, Net, Adjusted Operating Expenses and Adjusted EBITDA: ​ Product Revenues, Net $565.0 to $580.0 million Adjusted Operating Expenses (Excluding Stock-Based Compensation) $135.0 to $145.0 million Adjusted EBITDA (Excluding Stock-Based Compensation) $355.0 to $370.0 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1267565/000155837023008080/0001558370-23-008080-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.